Nano therapy, often referred to as nanomedicine or nanotherapy, involves the application of nanotechnology to diagnose, treat, and prevent diseases at the molecular and cellular levels. Nanoparticles and nanoscale materials are designed and engineered to interact with biological systems for targeted therapeutic purposes.
Latest Nano Therapy Companies Update
Nov 2023: Smith & Nephew (S&N) is purchasing CartiHeal, a biocompatible, off-the-shelf implant for injured joints made of coral, for a maximum of $330 million. This comprises a $180 million cash consideration up front, with an additional $150 million possible later based on performance. The deal is anticipated to be finalized in 2024's first quarter. In contrast to the previous buyer, this one is an established business with a market estimated at over $9 billion and plenty of cash to close the acquisition. Depending on the ultimate agreement's worth, investors in CartiHeal are expected to receive an average return of up to six times.
Jan 2023: To increase the range of bioconjugates it offers, Lonza has partnered with McSAF and Cristal Therapeutics in two new ventures. The partnerships are intended to make it possible to incorporate two cutting-edge conjugation platforms—Inside® from McSAF and CliCr® from Cristal Therapeutics—into the Lonza Bioconjugation Toolbox. This toolkit provides various customized solutions for selecting, developing, and producing bioconjugates to promote the advancement of bioconjugate-based therapeutics. A series of bioorthogonal reagents called CliCr technology from Cristal Therapeutics facilitates the production of various bioconjugates. The CliCr technology offers enhanced yields and wide applicability compatible with biochemically important reaction conditions. It is based on metal-free click chemistry.
The  nano therapy market is projected to reach USD 19.67 Billion by 2030 at 12.50% CAGR during the forecast period 2022-2030. Nanotechnology has the potential to improve the drug solubility, stability, half-lives, and efficiency of the treatment. Nano therapy is a modern technique for treatment of various diseases and performed with the help of submicron sized molecular devices or nanoparticles. Nanotechnology offers the possibility to enhance drug dissolvability and strength, drag out medication half-lives in plasma, minimize off target impacts, and gather drugs at an objective site. This technology is characterized as submicron estimated atomic gadgets or nanoparticles prevalently running from 5 to 500 nm in one dimension. Generous past exploration exertion has brought about techniques to fuse helpful operators into biocompatible Nano devices including polymer nanoparticles, liposomes, micelle frameworks, inorganic nanoparticles, nanotubes, and dendrites.
The market for Nano-therapy is blooming, as of now, around 250 Nano-medical products are being tested or used for humans. Nano therapy is majorly used in the treatment of diseases such as cancer, diabetes, cardiovascular disease and others. The major driving factors for the growth of the market are increasing the prevalence of cancer and other metabolic diseases. A recent study conducted by the Journal of Diabetes and Metabolic diseases has suggested the prevalence of MS ranged from 35.8 to 45.3 % in India and 30.5 to 31.5 % in China. Moreover, continuous development in technology, increasing demand for the better treatment, government support for research and development, and increasing healthcare expenditure of the people have fueled the growth of Nano therapy market. However, lack of regulatory standards in the examination of Nano therapy and higher cost of the treatment are the major factors that may restrict the growth of the market.
Key Players for Global Nano Therapy Market
Some of the major players for the nano therapy market are Smith and Nephew (UK), Selecta Biosciences, Inc. (US), Sirnaomics, Inc. (US), Tarveda Therapeutics (US), DIM (US), Cristal Therapeutics (the Netherland), CytImmune Science, Inc. (US), Luna (US), NanoBio Corporation (US), NanoBioMagnetics.n.nu (US), Nanobiotix (France), Nanoprobes, Inc. (US), Parvus Therapeutics (US), Nanospectra Biosciences, Inc (US), Nanosphere Inc. (US), NanoMedia Solutions Inc. (Japan).
Segmentation
The global Nano therapy market is segmented on the basis of technologies, applications and end users. On the basis of technology, the market is further segmented into nanomaterial and biological devices, Nano electronic biosensors, molecular nanotechnology, implantable cardioverter-defibrillators, and other. On the basis of applications, the market is segmented into cardiovascular disease, cancer therapy, diabetes treatment, rheumatoid arthritis, and others. On the basis of end users, the market is further divided into hospitals, clinics and research institutions.
 Regional Analysis
America dominates the global Nano therapy market owing to large diabetic population. According to National Diabetes Statistics Report, 2017, around 30.3 million people of all ages that is nearly 9.4% of the U.S. population had diabetes in 2015. Moreover, the accessibility of technology, increasing healthcare expenditure, and increasing government support for the research and development are some more factors supporting the growth in this region. Europe is the second largest nanotherapy markets, which is majorly driven by awareness and advancement in the nanotechnology sector. Asia Pacific is the fastest growing market owing to increasing demand for the better treatment options, and rising initiatives to include IT healthcare sector. Whereas, due to less development in technology, and low infrastructure level the market for Middle East & Africa will have limited growth in the nanotherapy market.
 Intended Audience
Nano Medical Devices Manufacturer and Supplier
Research and Development (R&D) Companies
Independent Research Laboratories
Market Research And Consulting Service Providers
Medical Research Laboratories
Academic Medical Institutes And Universities
Nano therapy Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)